Comparative Pharmacology
Head-to-head clinical analysis: ALEVE D SINUS COLD versus FENOPROFEN CALCIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALEVE D SINUS COLD versus FENOPROFEN CALCIUM.
ALEVE-D SINUS & COLD vs FENOPROFEN CALCIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor agonism in the nasal mucosa.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Naproxen 220 mg (as naproxen sodium) and pseudoephedrine HCl 120 mg orally every 12 hours; maximum 2 doses per 24 hours.
Oral: 300-600 mg every 6-8 hours as needed; maximum 3200 mg/day.
None Documented
None Documented
Naproxen: 12-17 hours (clinical: twice daily dosing); pseudoephedrine: 4-6 hours (clinical: every 4-6 hours).
Terminal elimination half-life is 2–3 hours; may be prolonged in elderly and patients with hepatic impairment.
Renal elimination: naproxen ~95% (mostly as unconjugated naproxen and 6-O-desmethyl naproxen), pseudoephedrine ~70-90% unchanged. Biliary/fecal: minor (<5% for each).
Primarily renal; approximately 90% of a dose is excreted in urine as glucuronide conjugates and unchanged drug; <2% excreted in feces.
Category C
Category C
NSAID/Decongestant Combination
NSAID